Episode
The New Pharmacy Playbook: Workforce Strength, AI Clarity, and 340B Reform | TWIRx
- Podcast
- This Week in Pharmacy
- Published
- Dec 5, 2025
- Duration seconds
- 3221
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/this-week-in-pharmacy-6992689/episodes/the-new-pharmacy-playbook-workforce-strength-ai-clarity-and-340b-reform-twirx/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/this-week-in-pharmacy-6992689/the-new-pharmacy-playbook-workforce-strength-ai-clarity-and-340b-reform-twirx.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This Week in Pharmacy – Friday, December 5th Strengthening the Pharmacy Workforce: A Conversation with Crystal Lennartz Cutting Through the AI Confusion: Shaun Jensen on Smarter Pharmacy OperationsThe New 340B Reality: Allison Arant on Navigating HRSA’s Rebate Model Welcome to another episode of This Week in Pharmacy, where we bring together the most important conversations, industry insights, and breaking pharmacy news shaping the future of healthcare. Today’s show features a powerhouse lineup of leaders driving innovation across retail pharmacy, technology, consulting, and 340B health-system strategy. 🟦 Segment 1 — Interview with Crystal Lennartz, President of Health Mart & Health Mart Atlas We open the show with a conversation with Crystal Lennartz, President of Health Mart and Health Mart Atlas, about the evolving role of workforce management in independent pharmacies. 📰 TWIRx News — Friday, December 5th A fast roundup of the top stories impacting pharmacy this week: 👉 Humana Exploring Partnership with Mark Cuban Humana is reportedly in discussions with Mark Cuban to explore a potential pharmacy partnership that could disrupt traditional PBM and drug-supply models. The collaboration may reshape how medications are priced and accessed—another sign that alternative pharmacy models are gaining traction. 👉 New Migraine Therapy: Symbravo Pharmacists should be aware of Symbravo, a new dual-action migraine therapy combining meloxicam and rizatriptan. Importantly, the product is non-substitutable, meaning pharmacies must dispense exactly as written. The therapy adds a new tool for acute migraine care but requires careful patient counseling on cardiovascular risks, medication-overuse headaches, and NSAID interactions. 👉 Walgreens Expands Automated Fulfillment Centers Wa…